Navigation Links
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
Date:12/11/2009

5 to 40 percent of AML patients, and a key prognostic factor of clinical outcome. Not only has AC220 demonstrated clinical activity in patients with FLT3 ITD mutations, but the drug has also been well tolerated. We look forward to continuing to evaluate the safety and efficacy of AC220 as a single agent in relapsed and refractory AML patients."

Phase 2 ACE Study Design

The ACE study is a single-arm, Phase 2 multinational clinical trial that will evaluate a 200 mg dose of AC220, taken orally once daily as a monotherapy treatment in FLT3 ITD-positive AML patients who have relapsed or are refractory after first-line AML therapy, age 60 years or older, or after second-line AML therapy or stem cell transplant, age 18 years or older. The co-primary endpoints of the study are overall composite complete remission rate and complete remission rate. Secondary endpoints include duration of remission, progression-free survival, overall survival, safety and tolerability. The ACE study is scheduled to enroll 180 patients across an estimated 100 sites in the United States, Canada, France, Germany, Italy, the Netherlands, Poland, Spain, and the United Kingdom. Screening at several sites in the United States has already commenced, and study initiation at additional sites in the United States, Canada and Europe is expected to commence in early 2010.

The study is based on data from a first-in-human Phase 1 clinical trial of AC220 presented earlier this month at the ASH meeting in New Orleans. The preliminary results from that trial in heavily pre-treated AML patients (median of four prior courses of therapy) with predominantly relapsed or refractory AML showed that AC220 was generally well tolerated up to and including once daily continuous dosing of 200 mg, and no treatment-related mortality was observed in the study. Responses were seen in both FLT3 ITD-positive and FLT3 ITD-negative AML patients, with an overall response rate of 56 and 20 pe
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
2. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
3. Cell Biosciences Acquires Protein Forest
4. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
5. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
6. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
7. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
8. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
9. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
10. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
11. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Patent Offering, The patent’s technology pertains to ... imaging within a body lumen (open space). Known ... low cost, single-use disposable illumination and camera module (housing). ... 2013 and the patent approval was received on January ... customize the lighting and magnification of the endoscope for ...
(Date:5/21/2015)... 2015 As part of its philanthropic ... Sun Health Foundation funded a $3.25 million project to ... with the most up-to-date features and technology. , The ... pharmacy's 45 staff members will begin moving from the ... the coming days. , The current pharmacy has ...
(Date:5/21/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... company focused on the development of autologous cell ... the International Society for Cellular Therapy (ISCT) on ... currently in a Phase 1/2 clinical trial.  The ... from 5:30 PM to 7:00 PM local time, ...
(Date:5/21/2015)... PA (PRWEB) May 21, 2015 ... has joined the firm as senior statistician and Principal, ... years of experience in the management and analysis of ... pharmaceutical and chemical industries. , “We’re delighted to have ... capabilities in data analytics,” said Dr. Philippe Cini, Group ...
Breaking Biology Technology:IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... Toronto Stock Exchange Symbol: MS, EDMONTON, Nov. ... leading developer in the treatment of multiple sclerosis ... been enrolled in its MAESTRO-03,U.S. pivotal phase III ... progressive multiple sclerosis (SPMS). An interim safety and,efficacy ...
... Alma Lasers Ltd., a global,leader in the development ... systems, today announced that it has,been named Israel,s ... 50 program. The program is presented by Deloitte ... growth over five years from,2002-2006. Howard Kelly, ...
... Associated with Chronic Pain Conditions in Patients Who ... ... FRAZER, Pa., Nov. 12 Cephalon, Inc. (Nasdaq:,CEPH) today announced ... Food and Drug Administration (FDA) seeking approval to,market FENTORA(R) (fentanyl buccal ...
Cached Biology Technology:BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 2BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 3Alma Lasers Ranked 9th in Deloitte Technology Fast 50 Award 2Cephalon Submits Supplemental New Drug Application for FENTORA 2Cephalon Submits Supplemental New Drug Application for FENTORA 3Cephalon Submits Supplemental New Drug Application for FENTORA 4Cephalon Submits Supplemental New Drug Application for FENTORA 5Cephalon Submits Supplemental New Drug Application for FENTORA 6Cephalon Submits Supplemental New Drug Application for FENTORA 7
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... mankind and the environment, there is a growing ... and education that new, more integrative approaches to ... multidisciplinary approaches to solving problems at the frontiers ... institutional level. , Integrated Science − New Approaches ...
... Actor and pancreatic cancer patient Patrick Swayze,s recent hospitalization ... system underscores the sensitivity of the lungs: many patients ... the disease itself. Lungs are delicate and exposed ... the body has developed an elaborate immuno-defense system to ...
... over the last few decades in old-growth forests of the ... worrisome trend is regional warming, according to a U.S. Geological ... 23. The study found that the increase in dying ... a wide variety of forest types, at all elevations, in ...
Cached Biology News:Research elucidates way lungs fight bacteria and prevent infection 2Tree deaths have doubled across the western US 2
... Round Well Plate Sterile ... wide range of 384-well ... high-throughput screening and research. ... assays and are suitable ...
Request Info...
... Antibody to Cytokeratin 5 / 6 ... molecular weight, basic type of cytokeratin expressed ... cell layers of stratified epithelia as well ... mesothelial cells and mesothelioma. Cytokeratin 6 (56 ...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Biology Products: